Dosimetry for molecular radiotherapy treatment planning (Stage 1 - no 23440)

分子放射治疗治疗计划的剂量测定（第 1 阶段 - 编号 23440）

• 批准号: 104958
• 金额: $ 4.11万
• 依托单位: MIRADA MEDICAL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104958
• 关键词: Dosimetry; molecular; radiotherapy; treatment; planning

"Molecular radiotherapy (MRT) is a treatment modality for cancer. It involves the administration of radioactive atoms with the aim of locally irradiating tumours. Dosimetry is concerned with the measurement of the absorbed radiation dose to each disease site. Many of the treatments in MRT are currently prescribed empirically or with a fixed quantity of radioactivity, without adequate dosimetry. This can lead to suboptimal treatment planning and patient over-exposure to radiation.The goal of this project is to develop a prototype software package for organ-level dosimetry, with the aim of improving treatment efficacy by optimization and personalisation of the administered dose. MRT treatments that are dosimetry-led are expected to produce improved outcomes - improved tumour control, longer survival, reduced symptoms and lower toxicities. Furthermore, patients who are unlikely to respond well to the treatment could be identified in advance, sparing them from unnecessary treatment and potential complications, as well as reducing the financial impact of these relatively high-cost treatments on the healthcare system. Our ultimate aim is to facilitate the wider implementation of dosimetry for molecular radiotherapy as to help improve cancer outcomes within the NHS."

“分子放射治疗（MRT）是癌症的一种治疗方式。它涉及放射性原子的管理，目的是局部照射肿瘤。剂量测定涉及测量每个疾病部位的吸收辐射剂量。MRT中的许多治疗目前是凭经验规定的或具有固定量的放射性，没有足够的剂量测定。该项目的目标是开发一个用于器官水平剂量测定的原型软件包，目的是通过优化和个性化管理剂量来提高治疗效果。以剂量学为主导的MRT治疗预计将产生改善的结果-改善肿瘤控制，延长生存期，减少症状和降低毒性。此外，可以提前识别不太可能对治疗反应良好的患者，使他们免受不必要的治疗和潜在的并发症，并减少这些相对昂贵的治疗对医疗保健系统的财务影响。我们的最终目标是促进更广泛地实施分子放射治疗的剂量测定，以帮助改善NHS内的癌症结局。"